4//SEC Filing
Hurley Ariel 4
Accession 0001415889-25-006608
CIK 0001597264other
Filed
Mar 3, 7:00 PM ET
Accepted
Mar 4, 5:20 PM ET
Size
17.4 KB
Accession
0001415889-25-006608
Insider Transaction Report
Form 4
Hurley Ariel
PRINCIPAL ACCOUNTING OFFICER
Transactions
- Sale
Common Stock
2025-03-03$89.63/sh−775$69,463→ 20,698 total - Sale
Common Stock
2025-03-03$92.00/sh−631$58,052→ 19,829 total - Sale
Common Stock
2025-03-03$93.42/sh−484$45,215→ 19,345 total - Sale
Common Stock
2025-03-03$95.16/sh−1,075$102,297→ 18,270 total - Sale
Common Stock
2025-03-03$90.92/sh−238$21,639→ 20,460 total - Award
Stock Option (Right to Buy)
2025-03-01$95.67/sh+7,007$670,360→ 7,007 totalExercise: $96.57Exp: 2035-02-28→ Common Stock (7,007 underlying) - Award
Common Stock
2025-03-01+6,506→ 21,473 total
Footnotes (8)
- [F1]The reported transaction involved the Reporting Person's receipt of a grant of 6,506 restricted stock units under the Issuer's 2024 Stock Incentive Plan.
- [F2]Effected pursuant to a trading plan adopted on September 12, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- [F3]The price reported is an average sale price. The shares were sold in multiple transactions ranging from $89.34 to $90.14. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported is an average sale price. The shares were sold in multiple transactions ranging from $90.36 to $91.21. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported is an average sale price. The shares were sold in multiple transactions ranging from $91.45 to $92.42. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The price reported is an average sale price. The shares were sold in multiple transactions ranging from $93.03 to $93.95. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F7]The price reported is an average sale price. The shares were sold in multiple transactions ranging from $95.15 to $95.36. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F8]This option vests with respect to 1/48th of the shares underlying the option on April 1, 2025 and as to an additional 1/48th of the shares underlying the option each month thereafter.
Documents
Issuer
Blueprint Medicines Corp
CIK 0001597264
Entity typeother
Related Parties
1- filerCIK 0001769740
Filing Metadata
- Form type
- 4
- Filed
- Mar 3, 7:00 PM ET
- Accepted
- Mar 4, 5:20 PM ET
- Size
- 17.4 KB